<DOC>
	<DOCNO>NCT02975583</DOCNO>
	<brief_summary>There medical therapy indicate reduction limb ischemic event . Studies dual-antiplatelet therapy aspirin clopidogrel versus aspirin alone ( CASPAR ) well study systemic anticoagulation ( WAVE ) show benefit either strategy reduction limb vascular event . Surgical bypass graft involves harvest vein , warm ischemia disruption vaso vasorum , ischemia-reperfusion , finally heighten hemodynamic stress new arterial environment . Vein graft rapidly remodel response increase blood flow pressure attempt normalize physiological range . The investigator previously identify 3 distinct temporal phase remodel process : During first 30 day follow implantation critical period luminal enlargement appear endothelium-independent process . The second phase occur 1 3 month represent period stiffen vein graft indicate synthesis fibrous protein . The third period refer biochemical remodel wherein vein recovers clinically measureable endothelial function . It likely diabetes mellitus impact phase . TRA2°P-TIMI 50 demonstrated reduction acute limb ischemic ( ALI ) event ( 42 % reduction ) urgent peripheral arterial revascularizations ( 35 % reduction ) , find unique among medical therapy . While temporal trend reduction ALI event occur early late exposure suggestion antithrombotic mechanism , reduction elective revascularization occur later suggest beneficial effect beyond platelet inhibition . The purpose trial study physiological impact vorapaxar low extremity bypass graft maturation function .</brief_summary>
	<brief_title>Vorapaxar Lower Extremity Bypass Grafts</brief_title>
	<detailed_description>Peripheral artery disease ( PAD ) characterize atherosclerotic occlusive disease low extremity . More 8 million Americans 200 million people globally PAD . Recent data reveal prevalence 15 % MEDICARE population . In population risk , patient history diabetes cigarette smoking , risk may rise high 30 % . In addition heighten risk myocardial infarction stroke , PAD increase risk low extremity claudication critical limb ischemia . Lower extremity bypass graft important method restore blood flow distal limb , reduce symptom claudication , prevent amputation patient severe PAD . Vorapaxar protease activate receptor ( PAR ) -1 antagonist inhibits thrombin activation PAR-1 receptor . Vorapaxar FDA approve patient PAD reduce rate cardiovascular death , MI , stroke , urgent coronary revascularization . It prohibit patient previous stroke . In addition , patient treat vorapaxar note significant reduction rate acute limb ischemia . This study randomize , double blind , placebo-controlled randomize study vorapaxar vs. placebo 80 patient undergoing femoral-popliteal bypass grafting Rutherford 3 - 5 disease . Baseline visit : Informed consent sign . Vital sign take blood drawn fast baseline value . First visit , pre-surgery : Blood drawn platelet activation test . A 6 minute walk test perform . Brachial artery reactivity test perform . An ankle-brachial index perform . 30 day : Platelet test perform . 90 day : Limited history physical exam . 180 day : Limited history exam , blood draw biomarkers , brachial artery reactivity test . Vein bypass graft reactivity test . 360 day : 6 minute walk test ankle brachial index perform . Randomization : The Investigational Pharmacy create block randomization . Patients active treatment group receive vorapaxar 2.08 mg daily match placebo . Treatment continue 1 year . In addition , 20 healthy subject serve control population define normal parameter single visit day . The healthy subject administer vorapaxar placebo .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Vorapaxar</mesh_term>
	<criteria>Male female , age 35 year older Atherosclerotic , infrainguinal PAD Rutherford class 35 plan low extremity bypass graft Adequate inflow index femoral artery Adequate popliteal , tibial , pedal revascularization target Willing comply protocol , attend followup appointment , complete study assessment , provide inform consent Complete occlusion iliac artery Aortoiliac occlusive disease severe common femoral artery disease Presence femoral , popliteal tibial aneurysm index limb Life expectancy le 2 year A vascular disease prognosis include anticipated ankle amputation index limb within 4 week index procedure Renal dysfunction define MDRD eGFR ≤ 30ml/min/173 m2 time screen Currently dialysis history renal transplant A document hypercoagulable state Nonatherosclerotic occlusive disease Current immunosuppressive medication , chemotherapy radiation therapy Absolute contraindication iodinate contrast</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Atherosclerosis</keyword>
</DOC>